These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8371457)

  • 1. From the Centers for Disease Control and Prevention. Public health focus: physical activity and the prevention of coronary heart disease.
    JAMA; 1993 Oct; 270(13):1529-30. PubMed ID: 8371457
    [No Abstract]   [Full Text] [Related]  

  • 2. Public health focus: physical activity and the prevention of coronary heart disease.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1993 Sep; 42(35):669-72. PubMed ID: 8361455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the cost-effectiveness of clinical and public health measures.
    Graham JD; Corso PS; Morris JM; Segui-Gomez M; Weinstein MC
    Annu Rev Public Health; 1998; 19():125-52. PubMed ID: 9611615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
    Barry M; Heerey A
    Ir Med J; 2002 May; 95(5):133-5. PubMed ID: 12092692
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
    Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and control of coronary heart disease and stroke--nomenclature for prevention approaches in public health: a statement for public health practice from the Centers for Disease Control and Prevention.
    Mensah GA; Dietz WH; Harris VB; Henson R; Labarthe DR; Vinicor F; Wechsler H;
    Am J Prev Med; 2005 Dec; 29(5 Suppl 1):152-7. PubMed ID: 16389142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins for cardiovascular prevention according to different strategies: a cost analysis.
    Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
    Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical inactivity as a risk factor for coronary heart disease: a WHO and International Society and Federation of Cardiology position statement.
    Bijnen FC; Caspersen CJ; Mosterd WL
    Bull World Health Organ; 1994; 72(1):1-4. PubMed ID: 8131243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.
    Turner DA; Paul S; Stone MA; Juarez-Garcia A; Squire I; Khunti K
    Heart; 2008 Dec; 94(12):1601-6. PubMed ID: 18450843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the Centers for Disease Control and Prevention. Public health: surveillance, prevention, and control of nosocomial infections.
    JAMA; 1992 Dec; 268(21):3048, 3052. PubMed ID: 1433724
    [No Abstract]   [Full Text] [Related]  

  • 13. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
    Martikainen JA; Ottelin AM; Kiviniemi V; Gylling H
    Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):265-72. PubMed ID: 17446806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifestyle modifications to prevent and control hypertension. 4. Recommendations on physical exercise training. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.
    Cléroux J; Feldman RD; Petrella RJ
    CMAJ; 1999 May; 160(9 Suppl):S21-8. PubMed ID: 10333850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.
    De Smedt D; Kotseva K; De Bacquer D; Wood D; De Backer G; Dallongeville J; Seppo L; Pajak A; Reiner Z; Vanuzzo D; Georgiev B; Gotcheva N; Annemans L
    Eur Heart J; 2012 Nov; 33(22):2865-72. PubMed ID: 22843446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updating recommendations for prevention of coronary heart disease.
    Zanchetti A
    J Hypertens; 1998 Oct; 16(10):1401-2. PubMed ID: 9814608
    [No Abstract]   [Full Text] [Related]  

  • 17. Should there be systematic screening of coronary heart disease in asymptomatic patients with risk factors alone? A decision analysis approach.
    Junod AF
    Diabetes Metab; 1998 Dec; 24(6):496-507. PubMed ID: 9932216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of accepted measures for intervention in coronary heart disease.
    Kuntz KM; Lee TH
    Coron Artery Dis; 1995 Jun; 6(6):472-8. PubMed ID: 7551268
    [No Abstract]   [Full Text] [Related]  

  • 19. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Siegel D; Swislocki AL
    JAMA; 1999 Feb; 281(5):417-9. PubMed ID: 9952198
    [No Abstract]   [Full Text] [Related]  

  • 20. Physical activity: the evidence of benefit in the prevention of coronary heart disease.
    Press V; Freestone I; George CF
    QJM; 2003 Apr; 96(4):245-51. PubMed ID: 12651969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.